It is also imperative that CF centers continue to share and publish their real-world experiences with patients on CFTR modulators to help better understand the potential short- and long-term AEs with these medications as well as patient characteristics that may be associated with higher risk of certain AEs. The gene discussed is CFTR; the disease is cystic fibrosis.